Boston Medical Sciences, Inc., headquartered in Chuo-ku, Tokyo, and led by Representative Director and CEO Masaki Okamoto, announced that it has raised ¥5.55 billion in its Series B financing round through a third-party allotment of new shares.
The round was co-led by Japan Growth Capital Investment Corporation (whose assets are managed by Nomura SPARX Investment, Inc.), Global Brain Corporation, and Beyond Next Ventures Inc.
